Background: We aimed at determining whether the pathogenic bacteria at the onset of disease are genetically different and whether this affects future choice of the therapeutic methods against group A β-hemolytic streptococcal acute pharyngitis/tonsillitis. Methods: A pharynx swab was collected from pediatric patients who visited our hospital. The swab was cultured, and hemolytic streptococcus was detected 230 times. We isolated pathogenic bacteria of patients infected more than once and examined the bacteria using pulse-field gel electrophoresis. Results: Based on gene search results, we found that if the period of developing relapse was within 1 month from the first infection, all patients had the same gene. However, all patients in whom reinfection occurred after 6 months or later had different pertinent genes. Conclusions: The number of relapse/reinfection is significant for this disease, and considerably caution is essential for its treatment. No changes to antibacterial drug administration may be necessary for the second administration unless more than 6 months have passed since the first infection.
 Japan Pediatric Respiratory Tract Disease Association/ Japan Pediatric infectious Disease Association, “Diagnosis Guideline of Pediatric Respiratory Organ infectious Disease,” Kyowa Kikaku, Tokyo, 2007.
 M. E. Pichichero and P. A. Margolis, “A Comparison of Cephalosporins and Penicillins in the Treatment of Group A Beta-Hemolytic Streptococcal Pharyngitis: A Meta-Analysis Supporting the Concept of Microbial Copathogenicity,” Pediatric Infectious Disease Journal, Vol. 10, No. 4, 1991, pp. 275-281. doi:10.1097/00006454-199104000-00002
 J. R. Casey and M. E. Pichichero, “Meta-Analysis of Cephalosporin versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis in Children,” Pediatrics, Vol. 113, No. 4, 2004, pp. 866-882. doi:10.1542/peds.113.4.866
 H. Sakata, “Comparative Study of 5-Day Cefcapene-Pivoxil and 10-Day Amoxicillin or Cefcapene-Pivoxil for Treatment of Group A Streptocpccal Pharyngitis in Children,” Journal of Infection and Chemotherapy, Vol. 14, No. 3, 2008, pp. 208-212. doi:10.1007/s10156-008-0597-0
 S. Keisuke, T. Nishimura, M. Takashi, I. Naoichi, Y. Takayoshi, W. Ehiro and F. Yoshitomo, “Investigation on Efficacy, Safety, and Pharmacokinetics of Granules of Cefcapene Pivoxil for Child in Pediatric Patients with Infectious Disease,” Journal of Chemical Engineering of Japan, Vol. 54, 2006, pp. 465-477.
 M. E. Pichichero, J. L. Green, A. B. Francis, S. M. Marsocci, M. L. Murphy, W. Hoeger, C. Noriega, A. Sorrento and J. Gootnick, “Recurrent Group A Streptococcal Tonsillopharyngitis,” Pediatric Infectious Disease Journal, Vol. 17, No. 9, 1998, pp. 809-815. doi:10.1097/00006454-199809000-00012
 T. Yuichiro, I. Izumi, M. Koji and I. Kazuo, “Efficacy of Cephalosporin Antibiotics in Acute Streptococcal Pharyngitis/Tonsillitis Patients,” Journal of the Japan Pediatric Society, Vol. 113, 2009, p. 318.
 J. M. Martin, M. Green, K. A. Barbadora and E. R. Wald, “Group A Streptococci among School-Aged Children: Clinical Characteristics and the Carrier State,” Pediatrics, Vol. 114, No. 5, 2004, pp. 1212-1219. doi:10.1542/peds.2004-0133
 F. Fitoussi, R. Cohen, G. Brami, C. Doit, N. Brahimi, F. Rocque and E. Bingen, “Molecular DNA Analysis for Differentiation of Persistence or Relapse from Recurrence in Treatment Failure of Streptococcus Pyogenes Pharyngitis,” European Journal of Clinical Microbiology and Infectious Diseases, Vol. 16, No. 3, 1997, pp. 233-237. doi:10.1007/BF01709587
 J. M. Musser, V. Kapur and J. Szeto, “Genetic Diversity and Relationships among Streptococcus Pyogenes Strains Expressing Serotype M1 Protein: Recent intercontinental Spread of Subclone Causing Episodes of Invasive Disease,” Infection and Immunity, Vol. 32, No. 3, 1995, pp. 994-1003.